Login to Your Account



Clinic Roundup


Wednesday, November 21, 2012
• Atox Bio Ltd., of Ness Ziona, Israel, reported top-line results from a Phase IIa trial showing that AB103, a short peptide immune regulatory therapy, produced meaningful improvement across multiple endpoints vs. placebo in patients with necrotizing soft-tissue infections.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription